Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02656394 · ClinicalTrials.gov registry record · Phase 2
Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101
A Phase 2 study, sponsored by Glia.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT02656394 is a Phase 2 study that has completed, run by Glia. The registered enrollment target is 49 participants.
The verdict
NCT02656394, a Phase 2 study, has completed, sponsored by Glia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of 0.5% GL101 topical gel administered twice daily for 28 days in ameliorating adverse ocular side effects in patients under ongoing treatment with glaucoma medications.
Interventions
- DRUG Placebo
- DRUG GL101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2016-01-22 |
| Est. Completion | 2018-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02656394
The ClinicalTrials.gov registry entry for NCT02656394 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glia, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02656394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02656394 about?
NCT02656394 is a clinical study titled "Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101". To evaluate the safety and efficacy of 0.5% GL101 topical gel administered twice daily for 28 days in ameliorating adverse ocular side effects in patients under ongoing treatment with glaucoma medications.
What is the current status of trial NCT02656394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2016-01-22. Estimated completion is 2018-12-30.
What interventions are being tested in trial NCT02656394?
The interventions under investigation include: Placebo (DRUG), GL101 (DRUG).
Who is sponsoring clinical trial NCT02656394?
This trial is sponsored by Glia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.